|
XENE Xenon Pharmaceuticals Inc 1582313 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-102,302,000.00 |
| Balance Sheet |
|
Current Assets
|
$1,106,632,000.00 |
|
Assets
|
$1,386,810,000.00 |
|
Current Liabilities
|
$39,815,000.00 |
|
Liabilities
|
$48,991,000.00 |
|
Equity
|
$1,337,819,000.00 |
|
Shares Out
|
96624123.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-88,897,000.00 |
|
Investing Cash Flow
|
$-407,282,000.00 |
| Market Analysis |
Market Cap
|
$6,202,302,455.37 |
|
Price
|
$61.30 |
|
BVPS
|
13.85 |
|
PB
|
4.63 |
|
EPS
|
-1.17 |
|
FCF
|
$-89,030,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:19 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:13 |
|
| Jan |
Feb |
Mar |
|
|
|
|
2026-02-26 |
-1.31 |
|
| Apr |
May |
Jun |
|
|
|
|
2026-05-07 |
-1.17 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-11 |
1.07 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-03 |
-1.15 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view XENE documents filed with the SEC.
XENE Filings
Clear
